Gain Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
GANX$1.08-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||
| · 2024 · 2023 | ||||||
| Net loss | | $(20,411,191) | | $(22,267,520) | ||
| Components of other comprehensive (loss) income | | | | | | |
| Unrealized gain on available-for-sale marketable securities | | | 4,974 | | | 89,304 |
| Changes in defined benefit pension plan obligation, net of tax | | | (132,524) | | | (127,601) |
| Foreign currency translation | | (367,240) | | 249,911 | ||
| Other comprehensive (loss) income, net of tax | | | (494,790) | | | 211,614 |
| Comprehensive loss | | $(20,905,981) | | $(22,055,906) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.